2022 Weekly Broadcast Archive

 Date  Content
5/24/2022 NRG-GY022: Temporary Closure on June 1, 2022
5/23/2022 Weekly Broadcast: NRG-GY012, NRG-BR004, GOG-0261, NRG-GY014, NRG-GY024, NRG-LU006
5/20/2022 NRG-BR004 Study Closure
5/20/2022 NRG Oncology Study Terminations
5/16/2022 Weekly Broadcast: NRG-BN001, NRG-GY022, NRG-BR003, NRG-BR004, NRG-BR007, NRG-GI004, NRG-GI005, NRG-GI008, NRG-CC005, GOG-0210, NRG-GY014, RTOG 1216, NRG-LU006
5/2/2022 Weekly Broadcast: NRG-BN004, NRG-BR004, NRG-GY014, NRG-GU005
4/29/2022 NRG-BR004 Temporary Closure
4/25/2022 NRG-BN007 Temporary Closure
4/25/2022 Weekly Broadcast: NRG-GY022, NRG-BR007, NRG-GI008, GOG-0210, GOG-0225, GOG-0238, GOG-0263, GOG-0278, GOG-0286B, NRG-GU007, NRG-HN008
4/18/2022 Weekly Broadcast: NRG-BN007, NRG-BN011, NRG-BR003, NRG-CC005. NRG-GI008, NRG-GU011, GOG-0210, NRG-GY018
4/15/2022 NRG-GY018 Central Monitoring Update
4/11/2022 Weekly Broadcast: NRG-BR003, GOG-0263, NRG-GY022, NRG-BN010, GOG-0210
4/4/2022 Weekly Broadcast: GOG-0263, NRG-GY018, NRG-HN004, NRG-GU005, NRG-GY022, NRG-BR003, NRG-BR004, GOG-0210
3/30/2022 NRG-BR003 Upcoming Closure to Accrual
3/28/2022 Weekly Broadcast: NRG-GU011, NRG-LU005, NRG-GY022, NRG-GI008, NRG-GU010, NRG-GU011, GOG-0210
3/21/2022 Weekly Broadcast: NRG-BN003, NRG-GY022, NRG-BR004, NRG-BR007, NRG-CC005, NRG-GI008, NRG-GU010, NRG-GU011, GOG-0210, GOG-0238, GOG-0258, NRG-LU006
3/17/2022 GOG-0238 Interim Analysis Results
3/16/2022 NSABP B-55 Press Release Olaparib results
3/15/2022 NSABP B-55: FDA approval & ESMO Plenary
3/14/2022 Weekly Broadcast: NRG-GI008, NRG-GU005, NRG-GI005, NRG-GI007, NRG-GU010, NRG-GU011, NRG-HN006, NRG-LU006
3/10/2022 NRG-GI008 Protocol Activation
3/7/2022 Weekly Broadcast: RTOG 0724, NRG-BN007, NRG-GY022, NRG-CC009, NRG-BN009, NRG-GI004, GOG-0210
3/2/2022 General Information on Potential Drug-Interactions of Concomitant CTEP IND Agents and the SARS-CoV-2 Antiviral Drug PAXLOVID
2/28/2022 Weekly Broadcast: NRG-GY014, NRG-GY025, NRG-GI007, RTOG 0724, NRG-GY012, NRG-DT001, NRG-GY022, NRG-BN010, NSABP/NCIC MA.32F, NRG-GI004, NRG-GU008, NRG-GU009, NRG-GU010, GOG 0210
2/22/2022 NRG-GY012: Temp Closure
2/21/2022 Weekly Broadcast: NRG-GY014, NRG-BR004, NRG-BR007, NRG-GU008, NRG-GU009, GOG-0210, RTOG 1308
2/14/2022 Weekly Broadcast: NRG-GY014, NRG-GY024, NRG-GY025, NRG-GY005, NRG-HN006, RTOG 1216, NRG-GU007
2/9/2022 First Participant Enrolled on FORTE
2/4/2022 NRG-BR004 Amendment 5 Activation
1/31/2022 Weekly Broadcast
1/24/2022 Weekly Broadcast: NRG-BR004, NRG-CC005 (FORTE)
1/17/2022 Weekly Broadcast:  RTOG 1005, NRG-CC005, NRG-GI004, NRG-GI005, NRG-GU011, NRG-LU005
1/10/2022 Weekly Broadcast: NRG-BR004, NRG-GI007, NRG-GU008, NRG-GU009, NRG-LU005
 1/3/2022 Weekly Broadcast: NSABP B-55, NRG-CC005, GOG-0274, NRG-HN009


Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.